Clinical Trial

Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The new recreational marijuana markets are contributing to polysubstance-impaired driving and other harms, especially when marijuana is used in combination with alcohol, by selling marijuana to obviously-intoxicated customers. In this study, the effectiveness of an intervention to reduce the risk of marijuana sales to obviously-intoxicated customers will be tested in the state-licensed recreational marijuana market in Oregon, one of the first states to ban such sales. The intervention will combine efforts by state regulators to increase deterrence of the state law prohibiting marijuana sales to obviously-intoxicated customers with training of store personnel to recognize signs of intoxication and refuse sales. It will also include testing the rate at which visibly intoxicated customers are refused alcohol at nearby establishments that sell alcohol either on-site or off-site
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-01-23; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-04-14
Status change: Enrolling by Invitation → Not Yet Recruiting 2024-08-15
Trial Details
NCT Number NCT06235632
Lead Sponsor Klein Buendel, Inc.
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA), Pacific Institute for Research and Evaluation, National Opinion Research Center
Conditions Alcoholic Intoxication, Automobile Accident, Cannabis
Enrollment 229 participants
Start Date 2024-01-15
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-05